CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
A concise volatility overview comparing balanced funds and the SP 500 during retirement, with implications for risk management.
24,544 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
CoreWeave delivers a record bookings quarter but sinks on concentration fears, while QQQ holds steady amid AI volatil...
Oil climbs to the $70 range as the Fed signals a tighter stance, renewing risk-off sentiment that weighs on Bitcoin. ...
Missed Sandisk's 580% rally? No worry. You can still ride the AI-driven chip surge with three smart stock picks, clea...
ServiceNow has faced a brutal market sell-off in 2026. This guide breaks down whether the decline creates a compellin...
Investors awakened to a rough start for cruise stocks as Norwegian Cruise Line Holdings shares slid. This piece break...
Backlogs can power stock moves, but they also raise questions about execution, risk, and long-term profitability. Thi...
Spotlighting two strong growth names that could exceed Summit Therapeutics in a year. Learn the catalysts, risks, and...
Have tech stocks finally run out of road? This data-driven exploration breaks down valuations, growth drivers, and ho...
Wake up to a clear, actionable investing briefing. This Thursday reads roundup distills ten essential market themes i...
The market has sprinted higher, and valuations feel stretched. History, however, shows that corrections are a normal ...
U.S. markets climbed as Cisco impressed with earnings and Cerebras Systems began trading. The AI-driven rally helped ...